Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S44121 dose-ranging anti-arrhythmic study in chronic heart failure patients with ICD
NL-OMON35783Phase 2Active, not recruiting
- Sponsor
- Servier
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of S44121 in chronic heart failure (CHF), left ventricular systolic dysfunction (LVSD) and ventricular arrhythmia (VA) (4 arms), sponsored by Servier. Primary endpoint: Average rate of premature ventricular complexes per hour over 48 hours at week 12. Started Oct 2011; status: active, not recruiting.
02
Drugs
S44121
03
Conditions
chronic heart failure (CHF)left ventricular systolic dysfunction (LVSD)ventricular arrhythmia (VA)
Beyond the preview
Go deeper on NL-OMON35783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35783.